Floatz logo

Igpro20

Syndromic Agammaglobulinemia

Memorial Sloan Kettering Cancer CenterUNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Syndromic Agammaglobulinemia cohort.

Asset / SponsorPhaseRating
Panzyga
Octapharma
Phase 3BB
Xembify
Grifols Therapeutics LLC
Phase 3B
Human Immunoglobulins
Monash University
Phase 2/3B
Humax-Cd20
M.D. Anderson Cancer Center
Phase 2B
Amoxicillin
Monash University
Phase 2/3B
Lenalidomide
M.D. Anderson Cancer Center
Phase 2B
Ciprofloxacin
Monash University
Phase 2/3B
Clavulanic Acid
Monash University
Phase 2/3B

Same molecule, other indications

Igpro20 is also rated in:

acquired immunodeficiencyActive
B
Indicative · Phase 3
60 / 100
View asset →
plasma cell myelomaActive
CC
Indicative · Phase 2
46 / 100
View asset →
common variable immunodeficiencyActive
NR
Indicative · Phase 2
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →